Abiraterone Acetate Safe Over Long Term in Patients With Advanced Castration-Resistant Prostate Cancer: Presented at EMUC
Abiraterone acetate (AA) can be safely administered for long periods without concurrent steroids in patients with advanced castration-resistant prostate cancer (CRPC), according to research presented here at the 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC). AA reduces levels of testosterone, oestradiol, and cortisol, but it increases levels of adrenocorticotropic hormone, deoxycorticosterone, and corticosterone, which could lead to hypokalaemia, hypertension, and fluid retention.
For the full story, Click Here



According to
The U.S. Food and Drug Administration has approved
According to the findings of a clinical study conducted by researchers from Umea University in Sweden, adult male patients of locally advanced prostate cancer can gain from addition of radiation to androgen deprivation therapy. The study found that the group which received radiotherapy along with hormone therapy had greater survival rate. The risk of death from prostate cancer was cut by half.